Company profile: CohBar
1.1 - Company Overview
Company description
- Provider of mitochondria-based therapeutics as a clinical-stage biotechnology company developing CB4211 for NASH and obesity, showing reduced liver damage biomarkers and glucose levels; CB5138 analogs in preclinical development for IPF and other fibrotic diseases, reducing lung fibrosis and inflammation; and a Mitochondrial Genome Mining platform to discover therapeutic peptides.
Products and services
- CB4211: Development-stage therapeutic for NASH and obesity showing positive effects in reducing biomarkers of liver damage and glucose levels
- Mitochondrial Genome Mining: Platform-scale technology that systematically discovers therapeutically relevant peptides from the mitochondrial genome
- CB5138 Analogs: Preclinical-stage peptides for IPF and other fibrotic diseases, showing significant reduction in lung fibrosis and inflammation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CohBar
Matrx Pharmaceuticals
HQ: Poland
Website
- Description: Provider of pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Matrx Pharmaceuticals company profile →
AbbVie
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and precision medicine across immunology, oncology, neuroscience, virology, and aesthetics. Offers HUMIRA for autoimmune conditions, IMBRUVICA for certain cancers, and RINVOQ for inflammatory diseases. Delivers genomics research and the AbbVie R&D Convergence Hub (ARCH) to integrate data and advance personalized drug discovery and treatment insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AbbVie company profile →
Futura Medical
HQ: United Kingdom
Website
- Description: Provider of proprietary transdermal solutions. Products include Eroxon, a topical gel for erectile dysfunction that helps men achieve an erection within 10 minutes without a prescription, and DermaSys, a patented platform for delivering treatments via the skin tailored to specific therapeutic indications and desired speed of onset and duration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Futura Medical company profile →
NPS Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapies for rare diseases, dedicated to making a difference in the lives of patients who often have few, if any, treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NPS Pharmaceuticals company profile →
Arrowhead Pharmaceuticals
HQ: United States
Website
- Description: Provider of RNAi therapeutics for genetically driven diseases with protein overproduction, leveraging the TRiM platform for ligand-mediated, tissue-specific delivery. Pipeline includes plozasiran (ARO-APOC3) for hypertriglyceridemia, zodasiran (ARO-ANG3) for mixed dyslipidemia, and ARO programs targeting RAGE, MUC5AC, and MMP7 for inflammatory and muco-obstructive lung diseases and idiopathic pulmonary fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arrowhead Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CohBar
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CohBar
2.2 - Growth funds investing in similar companies to CohBar
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CohBar
4.2 - Public trading comparable groups for CohBar
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →